Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

552

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

April 22, 2023

Conditions
Postoperative Nausea and VomitingBenzodiazepineHigh-risk Patients
Interventions
DRUG

Remimazolam

Remimazolam is infused at a rate of 0.25 mg/kg/h from end of anesthesia induction until 15 minutes before the end of surgery.

DRUG

Placebo

Normal saline is infused at a rate same as in the remimazolam group from end of anesthesia induction until 15 minutes before the end of surgery.

Trial Locations (10)

100034

Peking University First Hospital, Beijing

Unknown

Beijing Hospital of the Ministry of Health, Beijing

Beijing YouAn Hospital, Capital Medical University, Beijing

Fuwai Hospital Chinese Academy of Medical Sciences, Beijing

Tongji Hospital, Tongji Medical College of HUST, Wuhan

Wuhan Puai Hospital, Wuhan

Suzhou Municipal Hospital, Suzhou

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Peking University First Hospital

OTHER